1-[4'-(5-Methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-piperidine | 873933-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[4'-(5-Methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-piperidine
• 英文别名: 5-Methyl-3-[4-[4-(piperidin-1-ylmethyl)phenyl]phenyl]-1,2,4-oxadiazole
• CAS: 873933-29-0
• 化学式: C₂₁H₂₃N₃O
• 分子量: 333.433
• InChiKey: CFLHQHWCMYUIHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4'-(5-methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-carbaldehyde 在 三乙酰氧基硼氢化钠 、 sodium hydroxide 作用下， 以 溶剂黄146 、 1,2-二氯乙烷 、 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 1-[4'-(5-Methyl-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-piperidine
  参考文献：
  名称：

  Histamine-3 receptor antagonist

  摘要：

  该发明涉及一种根据此处定义的I式化合物，或其药用可接受的盐；含有I式化合物的药物组合物；一种治疗可能通过拮抗组胺H3受体而治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物施用上述的I式化合物；以及一种治疗以下疾病或症状的方法，包括抑郁症、情绪障碍、精神分裂症、焦虑障碍、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖、头晕、癫痫、晕动病、呼吸道疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道的高低动力和酸分泌，该方法包括向需要此类治疗的哺乳动物施用上述的I式化合物。

  公开号：

  US20060019998A1

文献信息

• HISTAMINE-3 RECEPTOR ANTAGONISTS
  申请人：Pfizer Products Incorporated

  公开号：EP1771449A1

  公开（公告）日：2007-04-11
• [EN] HISTAMINE-3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR D'HISTAMINE-3
  申请人：PFIZER PROD INC

  公开号：WO2006011043A1

  公开（公告）日：2006-02-02

  This invention is directed to a compound of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro- intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.
• Histamine-3 receptor antagonist
  申请人：Wager T. Travis

  公开号：US20060019998A1

  公开（公告）日：2006-01-26

  This invention is directed to a compound of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  该发明涉及一种根据此处定义的I式化合物，或其药用可接受的盐；含有I式化合物的药物组合物；一种治疗可能通过拮抗组胺H3受体而治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物施用上述的I式化合物；以及一种治疗以下疾病或症状的方法，包括抑郁症、情绪障碍、精神分裂症、焦虑障碍、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖、头晕、癫痫、晕动病、呼吸道疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道的高低动力和酸分泌，该方法包括向需要此类治疗的哺乳动物施用上述的I式化合物。